Why the Market Dipped But GSK (GSK) Gained Today
https://www.zacks.com/stock/news/2258816/why-the-market-dipped-but-gsk-gsk-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258816
Apr 19, 2024 - In the latest trading session, GSK (GSK) closed at $39.75, marking a +1.22% move from the previous day.
0
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
https://www.zacks.com/stock/news/2257993/biotech-stock-roundup-regn-sage-nmra-down-on-updates-itci-gains-on-study-success?cid=CS-ZC-FT-analyst_blog|stock_roundup-2257993
Apr 18, 2024 - Regeneron (REGN) and Sage Therapeutics (SAGE) are in focus on regulatory and pipeline updates.
0
GSK shingles vaccine shown 82% effective 11 years after vaccination
https://seekingalpha.com/news/4090624-gsk-shingles-vaccine-shown-highly-effective-11-years-after-vaccination?source=feed_sector_healthcare
Apr 17, 2024 - GSK (GSK) said studies showed that its top-selling shingles vaccine, Shingrix, had an 82% efficacy rate 11 years after vaccination in people aged 50 and older. Read more here.
0
GSK (GSK) Rises But Trails Market: What Investors Should Know
https://www.zacks.com/stock/news/2254111/gsk-gsk-rises-but-trails-market-what-investors-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2254111
Apr 11, 2024 - GSK (GSK) closed at $40.80 in the latest trading session, marking a +0.27% move from the prior day.
0
Will Pfizer's (PFE) New Drugs Provide a Boost to 2024 Sales?
https://www.zacks.com/stock/news/2253860/will-pfizer-s-pfe-new-drugs-provide-a-boost-to-2024-sales?cid=CS-ZC-FT-analyst_blog|zer_report_update-2253860
Apr 11, 2024 - Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
0
GSK, Pfizer-backed ViiV gets FDA okay for HIV drug for adolescents
https://seekingalpha.com/news/4087977-gsk-pfizer-backed-viiv-gets-fda-okay-for-hiv-drug-for-adolescents?source=feed_sector_healthcare
Apr 08, 2024 - ViiV Healthcare said it has received FDA approval for its drug Dovato in the treatment of HIV-1 infection in adolescents 12 years old and older. Read more here.
0
GSK (GSK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
https://www.zacks.com/stock/news/2251483/gsk-gsk-rises-yet-lags-behind-market-some-facts-worth-knowing?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2251483
Apr 05, 2024 - GSK (GSK) concluded the recent trading session at $41.19, signifying a +0.81% move from its prior day's close.
0
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2250492/are-you-a-growth-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2250492
Apr 04, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
GSK (GSK) Registers a Bigger Fall Than the Market: Important Facts to Note
https://www.zacks.com/stock/news/2249459/gsk-gsk-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2249459
Apr 02, 2024 - GSK (GSK) concluded the recent trading session at $41.79, signifying a -1.49% move from its prior day's close.
0
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2248353/are-you-a-value-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2248353
Apr 01, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Page 1>